Item Regulation On June 4, 2026, AIM ImmunoTech Inc. (the “ Company”) released an on-demand video presentation detailing previously published pre-clinical findings relating to the potential role of its lead drug candidate Ampligen® (rintatolimod) as a prophylactic and/or early-onset antiviral treatment for Ebola virus disease (“ EVD”). The Virtual Investor “ What This Means” segment is available for viewing at https://virtualinvestorco. com/aim. A copy of the press release relating to the video presentation is furnished as Exhibit 99.1 hereto and incorporated herein by reference. Additionally, an Investor Presentation slide deck of information related to the Company’s research into EVD is available for viewing on the Company’s website at https://aimimmuno. com/presentations, is furnished as Exhibit 99.2 hereto, and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-Looking Statements

Item Financial (d) Exhibits Exhibit Description No. 99.1 Press Release, dated June 4, 2026 ─────────────────────────────────────────────────────────────────────────────────────── 99.2 Investor Presentation Slide Deck, June 2026 104 Cover SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: AIM June 4, 2026 ImmunoTech Inc. ─────────────────────────────────────── /s/ Thomas Chief